Business Description
TuHURA Biosciences Inc
NAICS : 541714
SIC : 2833
ISIN : US8989201038
Total Employee Number:
22Description
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.78 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.1 | |||||
3-Year EPS without NRI Growth Rate | 9.7 | |||||
3-Year FCF Growth Rate | 2.3 | |||||
3-Year Book Growth Rate | -29.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.16 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.9 | |||||
9-Day RSI | 44.51 | |||||
14-Day RSI | 47.49 | |||||
3-1 Month Momentum % | 25.97 | |||||
6-1 Month Momentum % | 191.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.15 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 1.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.5 | |||||
Shareholder Yield % | -18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -171.41 | |||||
ROA % | -117.12 | |||||
ROIC % | -130.76 | |||||
3-Year ROIIC % | -75.06 | |||||
ROC (Joel Greenblatt) % | -2753.5 | |||||
ROCE % | -165.89 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.35 | |||||
Price-to-Tangible-Book | 196 | |||||
EV-to-EBIT | -4.62 | |||||
EV-to-Forward-EBIT | -9.56 | |||||
EV-to-EBITDA | -4.64 | |||||
EV-to-FCF | -5.11 | |||||
Earnings Yield (Greenblatt) % | -21.65 | |||||
FCF Yield % | -18.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TuHURA Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.524 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 47.49 | ||
| 14-Day ATR (€) | 0.158439 | ||
| 20-Day SMA (€) | 1.976 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.332 - 2.8 | ||
| Shares Outstanding (Mil) | 63.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TuHURA Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TuHURA Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| General meeting for 2025 | 2026-07-13 | In 13 days | ||
| H.C. Wainwright BioConnect Investor Conference | 2026-05-19 14:00 | 1.94 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.14 (+0.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 1.53 (+2.00%) | ||
| Annual report for 2025 | 2026-03-31 | 1.48 (-4.52%) | ||
| Citizens Life Science Conference | 2026-03-10 16:00 | 1.40 (+9.38%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 15:20 | 1.39 (+23.01%) | ||
| TuHURA Biosciences Corporate Update Call | 2025-12-11 08:30 | 0.85 (-11.92%) |
Show
Entries
TuHURA Biosciences Inc Frequently Asked Questions
What is TuHURA Biosciences Inc(STU:PL3)'s stock price today?
The current price of STU:PL3 is €1.96. The 52 week high of STU:PL3 is €2.80 and 52 week low is €0.33.
When is next earnings date of TuHURA Biosciences Inc(STU:PL3)?
The next earnings date of TuHURA Biosciences Inc(STU:PL3) is 2026-08-14 Est..
Does TuHURA Biosciences Inc(STU:PL3) pay dividends? If so, how much?
TuHURA Biosciences Inc(STU:PL3) does not pay dividend.
Press Release
Articles on TuHURA Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers